The Incidence and Prevalence of Inflammatory Bowel Disease Continues to Increase in the Faroe Islands – A Cohort Study from 1960 to 2020

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Kári Rubek Nielsen
  • Jóngerð Midjord
  • Søren Nymand Lophaven
  • Langholz, Ebbe
  • Turid Hammer
  • Johan Burisch
Background and Aims
The highest reported incidence rate of inflammatory bowel disease [IBD], and especially of ulcerative colitis [UC], is found in the Faroe Islands. This study aimed to assess the incidence rate and temporal trends in prevalence over six decades.

Methods
All incident and prevalent patients diagnosed with IBD between 1960 and 2020 from the nationwide and population-based Faroese IBD cohort were included in this study. All patients fulfilled the Copenhagen Diagnostic Criteria.

Results
Overall, 873 individuals were diagnosed with IBD during the study period, 559 [64%] with UC, 151 [17%] with Crohn’s disease, and 163 [19%] with IBD unclassified. A total of 59 patients had paediatric-onset IBD. The incidence of IBD continued to increase throughout the study period, as the age-standardized incidence rate started at 8 per 100 000 person-years [py] [European Standard Population, ESP] in 1960–79 and reached 70 by 2010–20. In 2021, the age-standardized period prevalence was 1414 per 100 000 persons. The IBD incidence was unevenly distributed among the islands with Sandoy having the highest rate of 106 per 100 000 py in 2010–2020.

Conclusions
The incidence of IBD continues to increase in the Faroe Islands, mainly driven by UC. The incidence shows an uneven geographical distribution, which suggests an adverse interaction between unknown environmental factors and genetic traits. The prevalence in 2021 corresponded to 1.3% of the Faroese population. Environmental risk factors are suspected to impact this homogeneous high-risk population; however, the reason for this is unclear.
OriginalsprogEngelsk
TidsskriftJournal of Crohn's and Colitis
Vol/bind18
Udgave nummer2
Sider (fra-til)308-319
Antal sider12
ISSN1873-9946
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
E.L. has served as advisory board member for Takeda and Ferring Pharmaceuticals and reports speakers fees from Tillotts, Janssen-Cilag, Takeda, MSD, and Ferring Pharmaceuticals. J.B. reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, and personal fees from Galapagos, outside the submitted work. Acknowledgments

Funding Information:
This work was supported by the Faroese Research Council, Torben & Alice Frimodts Foundation, Aage & Johanne Louis-Hansens Foundation, the Faroese Foundation, and Betri Foundation [to T.H.], but the work was made independently.

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved.

ID: 385129771